Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Baxter
Mallinckrodt
Harvard Business School
Dow
Express Scripts
Colorcon

Last Updated: February 1, 2023

Details for Patent: 8,778,997


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Which drugs does patent 8,778,997 protect, and when does it expire?

Patent 8,778,997 protects RAPIVAB and is included in one NDA.

This patent has forty patent family members in fourteen countries.

Summary for Patent: 8,778,997
Title:Antiviral treatments
Abstract: The invention provides unit dosage forms, kits, and methods useful for treating viral infections.
Inventor(s): Babu; Yarlagadda Sudhakara (Birmingham, AL), Chand; Pooran (Birmingham, AL), Bantia; Shanta (Birmingham, AL), Arnold; Shane (Hoover, AL), Kilpatrick; John Michael (Helena, AL)
Assignee: BioCryst Pharmaceuticals, Inc. (Birmingham, AL)
Application Number:13/103,562
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 8,778,997

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Biocryst RAPIVAB peramivir SOLUTION;INTRAVENOUS 206426-001 Dec 19, 2014 RX Yes Yes See Plans and Pricing See Plans and Pricing TREATMENT OF ACUTE UNCOMPLICATED INFLUENZA IN PATIENTS 2 YEARS AND OLDER See Plans and Pricing
Biocryst RAPIVAB peramivir SOLUTION;INTRAVENOUS 206426-001 Dec 19, 2014 RX Yes Yes See Plans and Pricing See Plans and Pricing TREATMENT OF ACUTE UNCOMPLICATED INFLUENZA IN ADULTS See Plans and Pricing
Biocryst RAPIVAB peramivir SOLUTION;INTRAVENOUS 206426-001 Dec 19, 2014 RX Yes Yes See Plans and Pricing See Plans and Pricing TREATMENT OF ACUTE UNCOMPLICATED INFLUENZA IN PATIENTS 6 MONTHS AND OLDER See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,778,997

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2006341592 See Plans and Pricing
Australia 2007215156 See Plans and Pricing
Australia 2013216632 See Plans and Pricing
Australia 2016262644 See Plans and Pricing
Brazil PI0621552 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Boehringer Ingelheim
Merck
Dow
McKesson
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.